UBX - Unity Biotechnology, Inc.
7.83 -0.12 (-1.50%)
After hours: 4:11PM EDT
| Previous Close | 7.65 |
| Open | 7.73 |
| Bid | 7.83 x 800 |
| Ask | 8.18 x 1000 |
| Day's Range | 7.39 - 8.22 |
| 52 Week Range | 7.39 - 24.56 |
| Volume | 312,047 |
| Avg. Volume | 198,865 |
| Market Cap | 340.713M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.40 |
- GlobeNewswire•20 days ago
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates
SAN FRANCISCO, March 06, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire•22 days ago
UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference
SAN FRANCISCO, March 04, 2019 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire•27 days ago
CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, Feb. 27, 2019 -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. , please note that in the first paragraph.
- GlobeNewswire•29 days ago
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, Feb. 25, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Benzinga•2 months ago
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
- GlobeNewswire•2 months ago
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced further expansion of the Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee with a cohort of an additional 24 patients at the highest evaluated dose (4mg) (Part B). Part B is intended to supplement the initial Phase 1 trial (Part A) by further evaluating the impact of UBX0101 on specific pro-inflammatory and extracellular matrix modifying factors within the Senescence-Associated Secretory Phenotype (SASP). To measure SASP factors, an adequate volume of synovial fluid is required in the knee joint capsule to collect a sample.
- PR Newswire•3 months ago
Ascentage Pharma Announces New License with Unity Biotechnology
ROCKVILLE, Md. and HONG KONG , Jan. 8, 2019 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other ...
- GlobeNewswire•3 months ago
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug (IND) application and executed the compound license agreement for the compound with Ascentage Pharma Group Corp Limited (“Ascentage Pharma”) under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema.
- American City Business Journals•4 months ago
This year's Bay Area IPO batch remains up 44% despite market turbulence
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
- Zacks•4 months ago
UNITY (UBX) Soars: Stock Adds 5.1% in Session
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- GlobeNewswire•4 months ago
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors
SAN FRANCISCO, Dec. 04, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- Benzinga•4 months ago
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- GlobeNewswire•4 months ago
UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence
- Event will be webcast live - SAN FRANCISCO, Nov. 13, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend.
- GlobeNewswire•5 months ago
UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results
SAN FRANCISCO, Nov. 07, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- GlobeNewswire•5 months ago
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results
SAN FRANCISCO, Oct. 31, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
- American City Business Journals•6 months ago
24 Bay Area companies have gone public so far this year. Here's how they've done.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
- Simply Wall St.•6 months ago
Do You Know Who Else Invests In Unity Biotechnology Inc (NASDAQ:UBX)?
If you want to know who really controls Unity Biotechnology Inc (NASDAQ:UBX), then you’ll have to look at the makeup of its share registry. Institutions often own shares in moreRead More...
- ACCESSWIRE•6 months ago
Today’s Research Reports on Stocks to Watch: Unity Biotechnology and Principia Biopharma
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC’s “Power Lunch” about the company’s plans. Amazon CEO Jeff Bezos is an investor in the company.
- Zacks•6 months ago
Unity (UBX) Catches Eye: Stock Jumps 8.8%
Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
CNBC•6 months agoUnity Biotech CEO: We can 'absolutely' create drugs that slow, halt or reverse diseases of aging
"The evidence is mounting, both in our company and outside, that you can intervene and you can change the course of these specific diseases," says Unity Biotechnology CEO Keith Leonard.
- CNBC•7 months ago
Why Jeff Bezos is backing this Silicon Valley scientist who is working on a cure for aging
Unity Biotechnology is a company designing drugs and treatments that can make a person functional and free of the diseases associated with aging for as long as possible. The company — backed by Jeff Bezos and Peter Thiel —went public in May and is listed on NASDAQ. Of the many people currently involved in searching for ways to slow down or delay the effects of growing older, Nathaniel David might actually have a shot.
